At 4 wk after intraperitoneal inoculation of murine cytomegalovirus (MCMV) in adult BALB/c mice, MCMV remained detectable only in the salivary glands. When T cells of these mice were activated by a single injection of antiCD3e monoclonal antibody, mice died of interstitial pneumonitis at 24-48 h after injection, accompanied by elevation of serum levels of TNF-a and ILFN-y. However, MCMV remained undetectable in the lungs during the period. Simultaneous injection of cyclosporin A reduced such effects of anti-CD3. In conclusion, although the presence of MCMV in the host may be required, MCMV-associated pneumonitis is not mediated by virus in the lung but probably by the cytokines released from T cells, of which responsiveness to stimulation via CD3 molecule has been presumably modified by MCMV infection. (J. Clin. Invest. 1994Invest. . 94:1019Invest. -1025 
Introduction
Human cytomegalovirus (CMV)' causes pneumonitis, retinitis, gastroenteric diseases, hepatitis, and encephalitis in immunomodulated or immunocompromised patients. Among them, pneumonitis is a serious concern because of its high frequency of occurrence, its high mortality, and lack of effective antiviral therapy. Murine CMV (MCMV) infection in mice resembles its human counterpart in many ways with respect to establishment of acute and chronic infections, viral persistency and latency, and host-virus interaction (1) . Recent results of studies on MCMV-associated pneumonitis in mice from several laboratories suggest that the presence of replicating MCMV alone in the lungs is not responsible for MCMV pneumonitis (2) (3) (4) . Unirradiated F1 hybrid mice infected with MCMV develop se-vere interstitial pneumonitis, when adoptively transferred with spleen cells of an uninfected parental mouse strain (2) . However, MCMV injection alone or induction of graft-versus-host (GvH) reaction alone, in F1 mice, does not lead to pneumonitis, even though the amount of virus in the lungs of the mice given with MCMV-induced GvH is similar to that in mice given MCMV alone (2) , suggesting that viral replication per se is not sufficient for the development of MCMV pneumonitis, and that events associated with immune response or immune reaction (severe GvH reaction, in this case) are required. When BALB/c mice are treated with a single dose of cyclophosphamide after MCMV infection, pneumonitis is induced, whereas it is not induced in severely immunosuppressed mice, who received continuous injections of cyclophosphamide, in spite of the presence of high titer of MCMV in the lungs (3) . In addition, athymic nude mice who receive MCMV do not develop pneumonitis, even though there is extensive replication of the virus (4) . Though MCMV is detectable in the lungs in all of these situations, all these results suggest that MCMV pneumonitis is not directly related to the ongoing MCMV replication in the lungs and raise a possibility that the systemic activation of host T cells, perhaps manifested by cytokine(s), may induce the pathogenic events for MCMV pneumonitis. To examine whether MCMV pneumonitis can occur in the absence of ongoing viral replication in the lungs, we use, in the present study, a mouse model of MCMV persistent infection, where MCMV does not exist in organs except the salivary gland, and T cells were activated by injection of anti-mouse CD3 monoclonal antibody.
Methods

Mice
Male BALB/c mice were provided from and bred in the Kyushu University Animal Center (Fukuoka, Japan). Mice were bred in isolated cages.
Virus and virus titration
Smith strain of MCMV was obtained from the American Type Culture Collection (Rockville, MD) and passed once in the primary culture of mouse embryo cells, which were prepared from 15-to 19-d-old BALB/c embryo and confirmed the absence of mycoplasma. The homogenate of infected mouse embryo cells was injected intraperitoneally to male BALB/c mice. At 2 wk after infection, the salivary glands were collected and supernatants of their homogenates were used as MCMV stock suspension. To determine tissue virus titer, organs were frozen, thawed, and homogenated in Eagle's minimal essential medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal calf serum, 10 mM Hepes, penicillin (500 U/ml), and streptomycin (0.1 mg/ml). The homogenates were titrated in loglo dilutions on subconfluent 3T3/Swiss albino cells in culture dishes (35 x 10 mm; Nunc, Roskilde, Denmark) and incubated for 90 min. Thereafter, monolayers were covered with methylcellulose, and plaques were counted 6 d later. Detection level of this assay was defined as 12.5 plaque forming units (PFU)/organ. Virus concentration of the MCMV stock suspension was 5 x 10' PFU/ml.
x 106 PFU. Supernatants of the homogenates of the salivary glands from noninfected mice were used as a control for mock infection. Antibodies against mouse CD3e (hamster IgG, clone 145-2C1I) and   mouse T cell receptor (TCR) ,B (hamster IgG, clone H-57-597) were  obtained by growing hybridoma cells in serum-free medium (SFM-101 ; Nissui, Tokyo, Japan). Antibodies were concentrated and purified by 50% ammonium sulfate precipitation. The purity of the preparations was confirmed by SDS-PAGE, and concentration of antibodies was determined by dye-binding assay using a protein-assay kit (Bio-Rad Laboratories, Richmond, CA).
Monoclonal antibodies
Detection of MCMV DNA in the organ DNA extraction from organs. Organs were removed, minced, and transferred into 4.5 ml of TNE buffer, which is composed of 10 mM Tris-HCI (pH 7.5), 100 mM NaCl, and 1 mM EDTA. Then, 0.5% SDS and 5 mg/ml of proteinase K (Sigma Chemical Co., St Determination of serum levels of TNF-cr, IFN-y, and IL-2 Serum levels of TNF-a, IFN-y, and IL-2 were measured by ELISA using commercial kits (Genzyme Corp., Cambridge, MA). Sera collected from individual mice were stocked at -80°C until the assay.
Blood chemistry
Serum levels of alkaline phosphatase, glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, total bilirubin, blood urea nitrogen, and creatinine were quantified by p-nitrophenyl phosphate assay, Karmen's method, Wroblenski-La due's method, alkaline azo-bilirubin assay, urease-GIDH assay, and Jaffe's method, respectively, using an autoanalyzer (model 736-10; Hitachi Ltd., Tokyo, Japan).
Light microscopy
Organs were removed after exsanguination and fixed in 3.7% formaldehyde at room temperature for 18 h. Sections were stained with hematoxylin-eosin. 
Results
Male BALB/c mice at 6 wk of age were inoculated intraperitoneally with 1 X I0W PFU (0.02 LD50) of MCMV. A high titer of MCMV was noted in the salivary glands even at 4 wk after inoculation (2.2 x 103 PFU). In the spleen and the lungs, infectious MCMV was detected at 10 and 15 d after inoculation, respectively, and it became undetectable by plaque assay (< 12.5 PFU/organ) and by PCR (see below) at 4 wk after inoculation. In the thymus and bone marrow, no virus was detected by plaque assay even at 5 d after inoculation. These persistently infected mice were injected intraperitoneally with anti-CD3e monoclonal antibody (anti-CD3 mAb, clone 145-2C1 1, hamster Ig) to activate T cells in vivo (8) . The mice persistently infected with MCMV showed piloerection and hypomotility beginning at 24 h after injection of anti-CD3 and died at times between 24 and 48 h with mortalities depending on the dose of anti-CD3 (Table I) . Even with the highest dose of anti-CD3 (200 /ig), mice of mock infection did not die and showed only slight piloerection and hypomotility followed by gradual restoration, whereas the same dose of anti-CD3 killed 93% of the mice infected persistently with MCMV. Pretreatment with ultraviolet irradiation of MCMV inoculum abrogated 1020 Tanaka et al. T cell stimulation by anti-CD3 mAb has been known to trigger the release of several cytokines both in clinical practice and animal models. These phenomena have been referred to as cytokine release syndrome or cytokine-related first injection syndrome (9) . Present findings of piloerection or hypomotility observed in the mice persistently infected with MCMV after anti-CD3 injection resemble the mice exhibiting cytokine release syndrome (10) . We found in the present study that systemic adverse reactions (piloerection, hypomotility, and death) were seen only after the first injection of anti-CD3 mAb, and none of the survivors after the first injection of mAb exhibited these findings and died upon the second injection of anti-CD3 mAb (data not shown). After anti-CD3 injection, serum levels of TNF-a were elevated at 12 h, and those of IFN-y were elevated at 6-12 h in the mice persistently infected with MCMV compared with their serum levels in mock infected mice. There was no difference in IL-2 levels between the two groups (Fig.  2 A) . When 10 mg/kg of cyclosporin A (CsA), an inhibitor of cytokine production (11, 12) , was simultaneously injected with anti-CD3 mAb to the mice persistently infected with MCMV on the day before and the day of anti-CD3 injection (50 Mg), serum levels of TNF-a, IFN-y, and IL-2 were significantly lower at 12 h after mAb injection than those in mice injected with anti-CD3 alone (Fig. 2 B) . The (Fig. 3 A) . In the thymus, the nuclei of a large fraction of cells in the cortex were fragmented (13) . However, nuclear fragmentation of thymocytes itself is by no means fatal to the host, though it may be related to elevated serum levels of cyto- kines (14) . In the spleen, destruction of lymphofollicles was noted, suggesting that some drastic events occur in response to anti-CD3 injection only in MCMV-infected mice. In the liver, although small necrotic lesions were seen, almost all of the liver cells remained intact. In the kidney, no pathological change was seen. In the lungs, however, histologically severe abnormalities were seen at 48 h after anti-CD3 injection in the mice persistently infected with MCMV ( Fig. 3 B, bottom right) . Marked thickening of alveolar septae with cellular infiltrations mainly with mononuclear cells and accumulation of amorphous material were observed (Fig. 3 B, inset) . As a result, diminution of alveolar spaces was noted. Additionally, no bleeding or emphysema was noted, and airways were kept intact. Although these histological findings were reported as histological characteristics of MCMV-associated interstitial pneumonitis (3), MCMV or its DNA could not be detected in the lungs as mentioned above (Fig. 1) . These morphological changes correlate to defective pulmonary function; SaO2 in the femoral artery determined by a pulse oxymetry was significantly lower than that in uninfected controls at 24-48 h after injection of 50 jug of anti-CD3 (78.8±10.7 vs 89.5±1.3%, n = 10, P < 0.01). These results indicate that mice with MCMV died of disturbance of ventilation, caused by MCMV-associated pneumonitis in "MCMVfree" lung. It is further suggested that these changes in the lungs may be mediated by cytokine(s) as mentioned above; that is to say, MCMV-associated pneumonitis might be one of the manifestations of cytokine release syndrome. This notion was further supported by the results shown in Fig. 2 B. Simultaneous injection of CsA with anti-CD3 mAb to the mice persistently infected with MCMV lowered serum levels of cytokines than those in mice injected with anti-CD3 alone (Fig. 2 B) , and remarkably diminished the cellular infiltrates to the alveolar septae (data not shown). As mentioned above, the mortality rate was also reduced from 42 to 10% by CsA treatment.
Discussion
The present indication that MCMV pneumonitis is mediated not by the presence of the virus in the lung but possibly by cytokines is supported by some clinical data. CMV pneumonitis 1022 Tanaka is one of the common risk factors in allogeneic organ transplantation. Previously, it had been explained that immunosuppression renders the host unable to control replication of the virus through a mechanism of reactivation or reinfection. However, recent studies on human CMV pneumonitis suggested that virus replication in the lung is unrelated to onset of CMV pneumonitis and that the host immune system participates in the pathogenesis of the disease (4, 15, 16) . This clinical concern was confirmed by the data on AIDS patients. 90% or more of patients with AIDS, whose CD4' T cells in the blood are significantly decreased in number, exhibit evidence of CMV infection; 50% or more develop CMV viremia (17) (18) (19) . Though manifestations of CMV disease in AIDS patients include retinitis, esophagitis, gastritis, hepatitis, and encephalitis, CMV pneumonitis is uncommon, in spite of the readily detectable infectious CMV in bronchoalveolar lavage fluid (20) (21) (22) (25, 26) . It is possible that syndromes such as retinitis and enteritis are due to the direct destructive effects of virus replication, whereas CMV pneumonitis may be mediated by cytokines but not by virus per se. In this study, it was not conclusively defined which cytokine, directly or indirectly, participates in pathogenesis of MCMV-associated pneumonitis. In silica-induced pulmonary fibrosis in mice, TNF is responsible for onset of the disease (27). Pulmonary fibrosis is a chronic feature of acute interstitial pneumonitis, suggesting that TNF may be one of the candidates to cause MCMV-associated pneumonitis. However, in the present model, it would also be possible that many cytokines comprehensively generated the pulmonary lesion. Still another unanswered question is why the lungs serve as the target organ. As shown in Fig. 3 , histological abnormalities were seen not only in the lungs but also in the thymus and the spleen. Though all of these three organs seem to be "cytokine-sensitive" in the mice persistently infected with MCMV, the pathological changes only in the lungs cause fatal reactions; the pathological changes in the thymus and the spleen are destructive to the organs but are not fatal to the host. Recently, Balthesen et al. (28) (29) reported that human CMV augments monokine mRNA expressions in infected monocytes. Similarly, human CMV enhances TNF-a gene expression (30) . In both reports, cells exposed to human CMV require the second signal, such as PMA-mediated or LPS-mediated signal, respectively, to release a massive amount of cytokines. In our present experimental model, anti-CD3 mAb was used to activate pan T cells. We consider the possibility that massive cytokine release can occur after treatment with superantigens or even nominal antigens. If this is true, the secondary infection by other microbes during persistent CMV infection may trigger CMV-associated pneumonitis in the host. Moreover, the present results of MCMVassociated interstitial pneumonitis cast a concern about the selection of the use of immunosuppressive agents in clinical allograft transplantation. Though clinical efficacy of anti-CD3 mAb for ongoing allograft rejection episode is well established, it should be kept in mind that this mAb has the possibility to cause severe cytokine release syndrome, including interstitial pulmonary lesions in the allograft recipients with persistent CMV infection (Table I) . Combined treatment of CsA with anti-CD3 would reduce morbidity of cytokine release syndrome, even when allograft rejection is resistant to CsA. In this connection, it must be mentioned that anti-TCR mAb does not appear to induce the syndrome in the host persistently infected with MCMV, in contrast to anti-CD3 mAb.
How persistent MCMV infection enhances the sensitivity of the host to the cytokine production-inducing activity of anti-CD3 is presently unknown. However, as virus-induced enhancement of cytokine gene expression was reported in influenza A virus (31, 32) and Coxsackie B virus (33) , it is possible that enhanced cytokine production after T cell stimulation is an omnipresent phenomenon in viral infection and virus-induced immunopathology.
